Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 700
- 试验地点
- 1
- 主要终点
- Number of participants that have achieved Low Disease Activity (LDA) at 12 months.
研究概览
简要总结
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.
详细描述
Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the study period.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
- •Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.
- •Participant is aged 18 years or older at enrolment.
排除标准
- •Participation in a clinical trial at enrolment.
结局指标
主要结局
Number of participants that have achieved Low Disease Activity (LDA) at 12 months.
时间窗: At 12 months
Number of participants that have achieved Minimal Disease Activity (MDA) at 12 months.
时间窗: At 12 months
Change from baseline in PROM scores at 12 months.
时间窗: At 12 months
次要结局
未报告次要终点